Key takeaway
Across 37 phase 3 trials with 50,171 adults with overweight or obesity, GLP-1 and multi-hormone drugs cut weight by 10.1% and systolic blood pressure by 4.9 mmHg versus placebo, and weight loss explained 76% of the differences in blood pressure effect between trials. This compares trial averages, not individuals, so it does not predict one person's response.
Study design
Evidence review
Reading basis
Published abstract
Reading focus
Design & applicability
The research question
Obesity and hypertension often occur together, and losing weight is a core strategy for lowering blood pressure. GLP-1 receptor agonists (GLP-1RAs) and newer multi-hormone receptor modulators (MHRMs) cause large weight loss with modest drops in blood pressure. The authors asked how closely the blood pressure reduction tracks the weight lost across these drugs.
Who and how
Systematic review and meta-analysis of phase 3 randomized controlled trials of GLP-1RAs and MHRMs in adults with overweight or obesity (PROSPERO CRD420251146441). Ovid MEDLINE, Ovid Embase, the Cochrane Database of Systematic Reviews and the Cochrane Central Register of Controlled Trials were searched from 1946 to December 2025. Risk of bias was assessed with the revised Cochrane tool. Placebo-adjusted changes in body weight and blood pressure at each trial's primary endpoint were pooled with random-effects meta-analysis, and meta-regression related weight loss to blood pressure reduction.
What it found
The authors’ reported results. Read each estimate with its population and uncertainty.
- 137 trials with 50,171 participants were analysed; 36 had low risk of bias across all domains. Half of participants (50%) were female, 16% had type 2 diabetes and 57% had hypertension. Median treatment duration was 68 weeks.
- 2Mean placebo-adjusted weight loss was -10.1% (95% CI -11.3 to -9.0), accompanied by a -4.9 mmHg (95% CI -5.5 to -4.3) reduction in systolic blood pressure.
- 3Across trials, 76% of the variance in systolic blood pressure reduction was explained by differences in weight loss (R² = 0.76; P < 0.01).
- 4That corresponded to a reduction of 0.37 mmHg (95% CI 0.28 to 0.45) per 1% change in body weight.
Limits & uncertainty
- 1Meta-regression compares trial-level averages, so it can show a pattern between trials but not that weight loss itself caused the drop in blood pressure in a given person.
- 2The trials differed in drugs, doses and populations, and the abstract does not report how much these accounted for beyond weight loss.
- 3Blood pressure was taken at each trial's primary endpoint, with a median treatment duration of 68 weeks, so longer-term effects are not shown.
- 4Based on the abstract only.
What to take from it
The average blood pressure benefit of these drugs tracks closely with how much weight is lost, which supports weight-loss therapy as an adjunct for blood pressure in obesity. It is not a promise for any one person, and it says nothing about whether to start or stop a medicine. Those decisions belong with a clinician.
Reading your own data
If you are working on weight and blood pressure, a smart scale and a validated upper-arm cuff are the right tools. Log weight weekly and blood pressure at consistent times, then compare multi-week averages rather than single readings, and share the trends with your clinician.
How to read this evidence
Check which designs were included, how searches and bias assessment were conducted, and the last search date. Publication date alone does not make the underlying evidence current.
Authors’ structured abstract English
The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.
Background
Obesity and hypertension frequently coexist, and weight-reduction is recommended as a core strategy for blood pressure (BP) management in adults with overweight or obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and emerging multi-hormone receptor modulators (MHRMs) induce substantial weight loss alongside modest BP reductions. However, the extent to which weight-loss is associated with BP lowering across these therapies remains unclear.
Methods
We conducted a systematic review and meta-analysis of phase 3 randomized controlled trials evaluating GLP-1RAs and MHRMs in adults with overweight or obesity (PROSPERO: CRD420251146441). We searched Ovid MEDLINE, Ovid Embase, the Cochrane Database of Systematic Reviews, and the Cochrane Central Register of Controlled Trials from 1946 to December 2025. Risk of bias was assessed using the revised Cochrane Risk of Bias tool. Placebo-adjusted changes in body weight and BP at each trial's primary endpoint were pooled using random-effects meta-analysis with inverse-variance weighting. Meta-regression assessed the association between weight loss and BP reduction.
Findings
Thirty-seven trials including 50,171 participants were analysed. Thirty-six trials had low risk of bias across all domains. Across all trials, 50% of participants were females, 16% had type 2 diabetes and 57% had hypertension. Median treatment duration was 68 weeks. Mean placebo-adjusted weight loss was -10.1% (95% CI -11.3 to -9.0) accompanied by a -4.9 mmHg (95% CI -5.5 to -4.3) reduction in systolic BP. Between-trial meta-regression showed that 76% of the variance in systolic BP reduction was explained by differences in weight loss (R^(2) = 0.76; P < 0.01), corresponding to a reduction of 0.37 mmHg (95% CI 0.28 to 0.45) per 1% change in body weight.
Interpretation
Across phase 3 trials of GLP-1RAs and MHRMs, greater weight loss was strongly associated with larger reductions in BP, supporting pharmacological weight-loss therapies as an adjunct strategy for BP management in obesity.
Funding
None.
Sources & attribution
Weight loss and blood pressure lowering with GLP-1 receptor agonists and multi-hormone receptor modulators in overweight and obesity: a systematic review and meta-regression of phase 3 clinical trials.
Nardone M, Kugathasan L, Daunt L, Parikh EJ, River Zhang HY, Pasricha SV, Orchanian-Cheff A, Cherney DZI, Odutayo A, Muskiet MHA.
EClinicalMedicine · 2026-10-12
DOI: 10.1016/j.eclinm.2026.104251 ↗PubMed · 42903654 ↗Europe PMC · Recorded licence: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
MoveVitals editorial interpretation · educational content · no individual clinical review recorded
Sources checked 2026-11-01
Practical guides
Read in context
Disrupted daily rest-activity rhythm is linked to higher mortality in 109,365 people
Across seven observational studies with 109,365 participants, a weaker day-night activity contrast (lower relative amplitude) was associated with higher cardiovascular mortality (hazard ratio [HR] 1.50, 95% CI 1.13 to 1.98) and all-cause mortality (HR 1.46, 95% CI 1.27 to 1.68). The evidence base is small and observational, so it cannot show that improving the rhythm lowers risk, and illness may itself disturb the rhythm.
Journal of the American Heart Association
Five exercise types lowered resting blood pressure, isometric training the most
Pooling 270 randomised trials with 15,827 participants, aerobic, resistance, combined, interval and isometric training all lowered resting blood pressure compared with non-intervention controls (P<0.001 for each), with the largest fall for isometric training: 8.24 mm Hg systolic and 4.00 mm Hg diastolic. The ranking between modes is partly indirect and the trials differ, so it is not a personal prescription.
British Journal of Sports Medicine
A salt substitute lowered stroke, major cardiovascular events and death in rural China
In 20,995 people in 600 rural Chinese villages who had a history of stroke or were 60 or older with high blood pressure, a salt substitute (75% sodium chloride, 25% potassium chloride) lowered the stroke rate versus regular salt over a mean 4.74 years: 29.14 versus 33.65 events per 1000 person-years (rate ratio 0.86, 95% CI 0.77 to 0.96; P = 0.006). Death was also lower (rate ratio 0.88) and serious hyperkalemia events were not significantly higher, but the trial was open-label and set in rural China.
The New England Journal of Medicine
Apple Watch irregular-pulse alerts were rare; 34% of those tested had atrial fibrillation
Among 419,297 Apple Watch users with no known atrial fibrillation (AF), 0.52% received an irregular-pulse alert, and 34% of the 450 who returned a usable ECG patch had AF (97.5% CI 29 to 39). Alerts that coincided with patch recording matched AF with a positive predictive value of 0.84 (95% CI 0.76 to 0.92), but only 20.8% of alerted people returned a patch and nobody without an alert was monitored, so a quiet watch does not rule AF out.
The New England Journal of Medicine

